NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)
ID: 353822Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353822

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-003.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the NHLBI Emerging Investigator Award (EIA), a federal grant aimed at providing long-term support for experienced researchers in heart, lung, blood, and sleep (HLBS) research. This award is designed for Program Directors/Principal Investigators (PDs/PIs) who currently manage at least two NHLBI R01-equivalent awards and have a proven track record of significant contributions to the field. The EIA allows for a flexible research program over a period of up to seven years, with funding of up to $700,000 per year in direct costs, and anticipates distributing up to $20 million annually across multiple awards. Applications will be accepted starting January 19, 2025, with a closing date of April 28, 2027. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-HL-26-003.html
    The National Heart, Lung, and Blood Institute (NHLBI) is reissuing the NHLBI Emerging Investigator Award (EIA) to offer long-term support for experienced researchers who are actively contributing to heart, lung, blood, and sleep (HLBS) research. The EIA, part of the R35 Outstanding Investigator Award mechanism, targets Program Directors/Principal Investigators (PDs/PIs) who have demonstrated significant contributions to the field and are currently managing at least two NHLBI-equivalent R01 awards, including one Early Stage Investigator award. The initiative provides funding for up to seven years, allowing researchers greater flexibility to pursue innovative projects without the constraints of predefined aims. It aims to foster ambitious research, reduce administrative burdens, and enhance mentoring efforts. Applications may request up to $700,000 per year in direct costs, and the program anticipates allocating up to $20 million annually across multiple awards. Eligible applicants include higher education institutions, non-profits, and government organizations, with an emphasis on increasing participation from diverse backgrounds. The funding opportunity opens for applications January 19, 2025, with an expiration date of April 29, 2027. The award emphasizes scientific merit and the potential impact of the proposed research on advancing HLBS science.
    Similar Opportunities
    NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NHLBI Outstanding Investigator Award (OIA), a federal grant aimed at supporting experienced Program Directors/Principal Investigators (PDs/PIs) engaged in heart, lung, blood, and sleep (HLBS) research. This award provides long-term funding of up to $700,000 annually for a maximum of seven years, allowing recipients to pursue innovative research initiatives without the constraints of predefined aims, thereby enhancing scientific productivity and flexibility. The OIA is designed to foster a stable research environment, reduce administrative burdens, and facilitate mentoring of junior scientists, with applications due by April 28, 2027. For further details, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-002.html.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NHLBI Early Phase Clinical Trials (R33), aimed at supporting investigator-initiated Phase I clinical trials for therapeutic and diagnostic interventions targeting heart, lung, blood, and sleep (HLBS) disorders. Applicants are required to be prepared to initiate their clinical trials within the first quarter of the project period and must demonstrate readiness in obtaining necessary regulatory approvals, including FDA and IRB, prior to the award. This funding is crucial for addressing unmet medical needs through innovative research, with a maximum budget of $1.515 million per year and a project duration of up to three years, contingent upon achieving specific milestones. Interested applicants should note the application deadline of June 4, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further details.
    NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NHLBI Career Transition Award (K22), a federal grant aimed at supporting postdoctoral fellows and doctoral-level researchers transitioning from intramural NIH research to independent extramural research. This program features a two-phase support structure: an up to two-year mentored intramural phase followed by a three-year extramural phase, contingent upon a successful review of the awardee's research progress. The grant is designed to cultivate future researchers capable of addressing critical health-related questions and enhancing the scientific community, with an emphasis on diversity and inclusion of underrepresented groups. Interested applicants must have a relevant doctoral degree and adhere to stringent application instructions, with proposals due starting September 12, 2024. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and the opportunity is open until July 12, 2027.
    NHLBI Program Project Applications (P01 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity for Program Project (P01) grant applications aimed at advancing research in heart, lung, and blood diseases. Applicants are required to submit proposals that include a minimum of three interrelated research projects focused on a common biomedical theme, with the option to incorporate clinical trials. This initiative is designed to foster collaborative research efforts and encourage innovative scientific directions, particularly supporting projects led by Early Stage Investigators (ESIs). The maximum funding for awarded projects is capped at $1.515 million annually, or $1.765 million if an ESI-led project is included, with a project duration of up to five years. Interested applicants can find more information and submit their proposals electronically via Grants.gov, with a closing date for applications set for September 25, 2026. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity (FON: PAR-24-173) aimed at supporting Phase I clinical trials for therapeutics and diagnostics related to heart, lung, blood, and sleep (HLBS) disorders in both adults and children. This initiative utilizes a bi-phasic R61/R33 award mechanism, where the R61 phase focuses on preparatory activities such as finalizing trial protocols and gathering preclinical data, while the R33 phase is dedicated to executing the clinical trial. The funding limits include up to $250,000 annually for the R61 phase and $1,515,000 for the R33 phase, with total support available for a maximum of five years. Interested applicants must adhere to NIH guidelines and submit their proposals by January 7, 2027, to be considered for this opportunity. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NHLBI Career Transition Award (K22) aimed at supporting postdoctoral fellows and research trainees in transitioning their research programs to extramural institutions as junior investigators. This grant provides a structured five-year program, which includes a mentored intramural phase of up to two years followed by an independent extramural phase lasting three years, contingent upon successful progress during the mentored phase. The program is designed to cultivate a diverse pool of skilled investigators to meet national biomedical research needs, with eligibility requirements including a doctoral degree and a maximum of five years of postdoctoral research experience within the NHLBI. Interested applicants should note that the application deadline is July 12, 2027, and they can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found in the full announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-209.html.
    Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research (R21)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research (R21)" to support exploratory research utilizing existing biospecimens relevant to heart, lung, and blood diseases. This grant aims to enhance the scientific utility of the NHLBI Biologic Specimen Repository by encouraging researchers to generate preliminary data that can inform future studies, with a focus on maximizing the value of stored collections. A total of $1,155,000 is anticipated for competitive awards from FY2023 through FY2025, with individual budgets capped at $75,000 for a maximum two-year project period. Interested applicants must submit their proposals by December 10, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Limited Competition: Physician Scientist Transition to Independence in Blood Science Research (R00 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Heart, Lung, and Blood Institute (NHLBI), has announced a Limited Competition Funding Opportunity titled "Physician Scientist Transition to Independence in Blood Science Research" (R00 - Clinical Trial Optional). This initiative aims to support the transition of outstanding blood science researchers with clinical doctorate degrees from mentored research positions to independent faculty roles, providing up to three years of funding for innovative research in blood science. The program is particularly focused on enhancing the scientific workforce by promoting diversity and fostering independent research careers that address critical health challenges in hematology. Interested applicants must submit their proposals by March 28, 2025, with a total funding ceiling of $250,000 available for new awards, and can direct inquiries to grantsinfo@nih.gov for further information.
    Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity for exploratory R21 grant applications focused on secondary analyses of existing human datasets related to heart, lung, blood diseases, and sleep disorders. The objective of this grant is to stimulate innovative research by utilizing existing datasets to explore novel scientific ideas and develop impactful biomedical tools and technologies, without the need for new primary data collection. This initiative is crucial for advancing public health research aligned with NHLBI priorities, with an annual funding commitment of up to $2,187,000 over three years, supporting approximately eighteen new awards each year, with a maximum of $75,000 in direct costs per application for a two-year project period. Interested applicants can find more information and application guidelines at NIH Grants, and should note that the application deadline is January 7, 2026.
    NCI Outstanding Investigator Award (R35 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NCI Outstanding Investigator Award (R35), aimed at providing long-term support for exceptional cancer research projects. This grant opportunity is designed for accomplished investigators with a proven track record in cancer research, allowing them to pursue innovative and high-risk projects that could lead to significant advancements in the field. The award offers up to $600,000 in direct costs per year for a maximum duration of seven years, with applications due by November 7, 2024. Interested applicants can find more information and contact details at the provided link: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-045.html.